US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Health Innovation Active ETF

34.42

+0.13980.41%

Post-market: 34.420.00000.00%16:18 EDT

Volume:3K

Turnover:109.54K

Market Cap:13.77M

PE:- -

High:34.47

Open:34.47

Low:34.15

Close:34.28

52wk High:34.86

52wk Low:25.79

Shares:400.00K

Float Shares:400.00K

Volume Ratio:2.61

T/O Rate:0.80%

Dividend:0.08

Dividend Rate:0.24%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Correction: Eisai, Biogen Secure China's Nod for Self-Injection Version of Leqembi

MT Newswires Live

Stoke Therapeutics, Biogen present long-term data on Zorevunersen

Stoke Therapeutics, Biogen Report 4-Year Open-Label Data for Dravet Drug Zorevunersen Showing Durable Seizure Reduction

Stoke Therapeutics and Biogen Present Long-Term Clinical Data That Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16TH European Epilepsy Congress (Eec)

THOMSON REUTERS

Perrigo Co. PLC Stock Underperforms Thursday When Compared to Competitors

Edwards Lifesciences Corp. Stock Outperforms Competitors Despite Losses on the Day

Gilead Sciences Inc. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains

Eisai’s Lenvima Combo Trial in Liver Cancer Ends With Mixed but Market-Relevant Results

Gilead’s Arcus-Backed Cancer Trial Reaches Completion, Setting Up a Key Immuno-Oncology Catalyst

Summit Therapeutics Says it is Beating Merck with Its Cancer Drug

Eikon Therapeutics Names Ching-Pin Chang as Chief Scientific Officer

Biogen, Eisai announce NMPA of China approves subcutaneous Leqembi

Nokia announces commercial agreement with BeeHealthy

Gan&Lee Receives Clinical Trial Approval for GZC8072 Tablet in New Indication

ST Renfu Initiation of Phase II Clinical Study for Novel Postoperative Pain Candidate

EDX Medical ramps up cancer and pneumonia diagnostics as losses widen amid growth push

EKF Diagnostics cancels 50,000 shares in latest buyback move

Jefferies Reaffirms Their Hold Rating on Merck KGaA (0O14)

Nokia and BeeHealthy bring network-based verification to digital healthcare

Biogen : Piper Sandler Raises Target Price to $245 from $225

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/BMED/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BMED","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","market":"US","secType":"STK","nameCN":"iShares Health Innovation Active ETF","latestPrice":34.42,"timestamp":1788465600000,"preClose":34.2802,"halted":0,"volume":3201,"hourTrading":{"tag":"盘后","latestPrice":34.42,"preClose":34.42,"latestTime":"16:18 EDT","volume":7,"amount":241.53,"timestamp":1788466684460,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0040781559034078286,"floatShares":400000,"shares":400000,"eps":0,"marketStatus":"Not Yet Opened","change":0.1398,"latestTime":"09-03 16:00:00 EDT","open":34.47,"high":34.47,"low":34.15,"amount":109541,"amplitude":0.009335,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788508800000},"marketStatusCode":0,"adr":0,"exchange":"ARCA","adjPreClose":34.2802,"sharesOutstanding":360000,"nav":34.280916,"aum":13712366.4,"dividendRate":0.002362,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":34.42,"preClose":34.42,"latestTime":"16:18 EDT","volume":7,"amount":241.53,"timestamp":1788466684460,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.609652868720226,"impliedVol":0.2836,"impliedVolPercentile":0.7649},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","floatShares":400000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.609652868720226,"shares":400000,"dividePrice":0.0813,"high":34.47,"amplitude":0.009335,"preClose":34.2802,"low":34.15,"week52Low":25.794,"pbRate":"--","week52High":34.86,"institutionHeld":0,"latestPrice":34.42,"eps":0,"divideRate":0.002362,"volume":3201,"delay":0,"ttmEps":0,"open":34.47,"prevYearClose":30.32,"prevWeekClose":33.8786,"prevMonthClose":33.8091,"prevQuarterClose":30.62,"fiveDayClose":34.5006,"twentyDayClose":31.3112,"sixtyDayClose":28.6562},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BMED\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"BMED","amount":0.08118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Health Innovation Active ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2023-12-20","symbol":"BMED","amount":0.007207,"announcedDate":"2023-12-20","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"BlackRock Future Health ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BMED\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.007207,"currency":"USD"},{"executeDate":"2026-06-15","recordDate":"2026-06-15","paymentDate":"2026-06-18","value":0.08118,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BMED\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BMED\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664138186","title":"Correction: Eisai, Biogen Secure China's Nod for Self-Injection Version of Leqembi","url":"https://stock-news.laohu8.com/highlight/detail?id=2664138186","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664138186?lang=en_us&edition=fundamental","pubTime":"2026-09-04 13:52","pubTimestamp":1788501121,"startTime":"0","endTime":"0","summary":"China's National Medical Products Administration  approved Eisai  and Biogen's subcutaneous autoinjector version of anti-amyloid beta protofibril antibody Leqembi as an initiation treatment for mild cognitive impairment due to Alzheimer's disease or mild AD dementia.The self-administered autoinjector is given once weekly at 500 mg through two 250 mg injections, according to a joint release on Thursday.The approval adds at-home subcutaneous treatment to the existing every-two-week intravenous regimen, with patients able to switch between the two administration methods during treatment, the release said.The product will be launched during Eisai's fiscal 2026, ending March 31, 2027.Shares of Eisai rose nearly 2% at market close.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4532","BK4585","LU0320765992.SGD","IE00B19Z9Z06.USD","BK4139","BK4533","PBE","BIIB","LU0109394709.USD","LU0889565916.HKD","IE00B894F039.SGD","IE00B19Z9P08.USD","BMED","LU0234570918.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664807150","title":"Stoke Therapeutics, Biogen present long-term data on Zorevunersen","url":"https://stock-news.laohu8.com/highlight/detail?id=2664807150","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664807150?lang=en_us&edition=fundamental","pubTime":"2026-09-04 07:40","pubTimestamp":1788478812,"startTime":"0","endTime":"0","summary":"“Stoke Therapeutics (STOK) and Biogen Inc. (BIIB) announced presentations of data at the 16th European Epilepsy Congress taking place September 5-9...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/stoke-therapeutics-biogen-present-long-term-data-on-zorevunersen-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/stoke-therapeutics-biogen-present-long-term-data-on-zorevunersen-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIIB","LU0234570918.USD","PBE","LU0889565916.HKD","BK4007","BK4139","IE00B894F039.SGD","BMED","IE00B19Z9Z06.USD","IE00B19Z9P08.USD","BK4588","LU0109394709.USD","LENZ","EPV","BK4539","BK4532","BK4533","BK4585","LU0320765992.SGD","STOK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664807353","title":"Stoke Therapeutics, Biogen Report 4-Year Open-Label Data for Dravet Drug Zorevunersen Showing Durable Seizure Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2664807353","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664807353?lang=en_us&edition=fundamental","pubTime":"2026-09-04 07:30","pubTimestamp":1788478227,"startTime":"0","endTime":"0","summary":"Stoke Therapeutics, Biogen report 4-year open-label data for Dravet drug zorevunersen showing durable seizure reductionStoke Therapeutics, Biogen flagged long-term zorevunersen data for Dravet syndrom","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDLCgQYh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","LU0234570918.USD","LU0320765992.SGD","PBE","BK4139","LU0889565916.HKD","BK4585","BK4532","BK4588","IE00B894F039.SGD","STOK","IE00B19Z9P08.USD","BIIB","BMED","IE00B19Z9Z06.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664380733","title":"Stoke Therapeutics and Biogen Present Long-Term Clinical Data That Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16TH European Epilepsy Congress (Eec)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664380733","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664380733?lang=en_us&edition=fundamental","pubTime":"2026-09-04 07:30","pubTimestamp":1788478200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nTUA8DKTRL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BMED","BK4139","PBE","BIIB","BK4532","LU0320765992.SGD","IE00B894F039.SGD","LU0234570918.USD","BK4533","IE00B19Z9P08.USD","STOK","BK4585","BK4588","LU0109394709.USD","LU0889565916.HKD","IE00B19Z9Z06.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664804473","title":"Perrigo Co. PLC Stock Underperforms Thursday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2664804473","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664804473?lang=en_us&edition=fundamental","pubTime":"2026-09-04 05:29","pubTimestamp":1788470940,"startTime":"0","endTime":"0","summary":"DJ Perrigo Co. PLC Stock Underperforms Thursday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Perrigo Co. PLC  slipped 1.52% to $14.27 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index  rising 1.06% to 7,747.71 and the Dow Jones Industrial Average  rising 1.18% to 53,686.11.Perrigo Co. PLC closed 39.74% below its 52-week high of $23.68, which the company achieved on September 5th.The stock demonstrated a mixed performance when compared to some of its competitors Thursday, as Johnson & Johnson  rose 1.17% to $278.43, Procter & Gamble Co.  fell 0.49% to $146.92, and Abbott Laboratories  fell 1.52% to $108.79.Data source: Dow Jones Market Data, FactSet. Data compiled September 3, 2026.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RXL","SG9999002232.USD","LU1914381329.SGD","TRUO","IE00BSNM7G36.USD","IE000M9KFDE8.USD","ABT","LU0114720955.EUR","FHLC","LU0266013472.USD","LU1989763690.USD","MEDX","SG9999001176.SGD","LU1244550577.SGD","IHI","IE0000B7K699.USD","LU2487616109.SGD","TMED","JDOC","IE00BFMHRM44.USD","LU2211815571.USD","IXJ","BK4581","GDOC","FTXH","LU2237957902.USD","IYH","BK4566","LU0795875169.SGD","XLP","XLV","PRGO","BK4082","LU0234572021.USD","PJP","VHT","LU1868836757.USD","IE00BVYPNW00.USD","IE000SO60NU8.SGD","LU0820561818.USD","UGE","IHE","LU1145028129.USD","LU2756315664.SGD","PG","BMED","SG9999013999.USD","TRUH","FSTA","JNJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664804316","title":"Edwards Lifesciences Corp. Stock Outperforms Competitors Despite Losses on the Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2664804316","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664804316?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:50","pubTimestamp":1788468600,"startTime":"0","endTime":"0","summary":"DJ Edwards Lifesciences Corp. Stock Outperforms Competitors Despite Losses On The DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Edwards Lifesciences Corp.  shed 1.15% to $89.78 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index  rising 1.06% to 7,747.71 and the Dow Jones Industrial Average  rising 1.18% to 53,686.11.Edwards Lifesciences Corp. closed 6.76% below its 52-week high of $96.29, which the company achieved on July 7th.The stock demonstrated a mixed performance when compared to some of its competitors Thursday, as Abbott Laboratories  fell 1.52% to $108.79, Medtronic PLC  rose 1.00% to $93.10, and Stryker Corp.  fell 1.35% to $307.99.Trading volume  remained 2.4 million below its 50-day average volume of 4.3 M.Data source: Dow Jones Market Data, FactSet. Data compiled September 3, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4504","LU1670628061.USD","LU1506573853.SGD","LU0528227936.USD","SYK","LU2468319806.SGD","AGNG","IE00BYQQ9H92.USD","BK4566","BK4592","TMED","LU1244550494.USD","LU0106261372.USD","IE00BQXX3F31.USD","LU0158827948.USD","LU2362541513.USD","LU2089283258.USD","PJP","LU2324357040.USD","LU2089984988.USD","LU0114720955.EUR","SG9999002232.USD","IHI","EW","IE00BN0W2W23.USD","LU0882574055.USD","BK4585","BMED","LU0976567544.SGD","LU2506952097.USD","LU1244550577.SGD","IE000M9KFDE8.USD","ABT","LU1023059063.AUD","GB00B4QBRK32.GBP","BK4082","LU0265550359.USD","LU2111349929.HKD","LU2237957811.SGD","SG9999004303.SGD","LU0058720904.USD","LU0006306889.USD","IE00BJT1NW94.SGD","LU0823416689.USD","LU2028103732.USD","MDT","LU1061106388.HKD","LU0289739699.SGD","IE00B3T34201.USD","LU1116320901.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664012018","title":"Gilead Sciences Inc. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2664012018","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664012018?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:35","pubTimestamp":1788467700,"startTime":"0","endTime":"0","summary":"DJ Gilead Sciences Inc. Stock Underperforms Thursday When Compared To Competitors Despite Daily GainsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Gilead Sciences Inc.  advanced 1.08% to $151.22 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index  rising 1.06% to 7,747.71 and the Dow Jones Industrial Average  rising 1.18% to 53,686.11.Gilead Sciences Inc. closed 3.86% short of its 52-week high of $157.29, which the company reached on February 11th.The stock demonstrated a mixed performance when compared to some of its competitors Thursday, as Johnson & Johnson  rose 1.17% to $278.43, Pfizer Inc.  fell 0.72% to $28.81, and Abbott Laboratories  fell 1.52% to $108.79.Trading volume  remained 2.3 million below its 50-day average volume of 6.8 M.Data source: Dow Jones Market Data, FactSet. Data compiled September 3, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509101.SGD","LU1061106388.HKD","LU1934455194.USD","LU2357627491.SGD","IBBQ","LU0234570918.USD","MEDI","SG9999015952.SGD","IE00BSNM7G36.USD","SG9999015986.USD","BK4550","BK4566","IE00BZ1G4Q59.USD","LU0289739699.SGD","LU0889565916.HKD","IE00B3T34201.USD","LU0965509283.SGD","LU0058720904.USD","LU1674673691.USD","BK4583","BK4139","LU0965509010.AUD","LU0882574055.USD","LU1057294990.SGD","LU1571399168.USD","BMED","BIB","LU2087621335.USD","LU2112291526.USD","LU2089984988.USD","BK4588","IE00B7SZLL34.SGD","LU1037948897.HKD","LU0823416689.USD","LU0109394709.USD","LU1934455277.USD","LU2324357040.USD","LU0859254822.USD","LU1934455863.HKD","LU1037948541.HKD","IE0002270589.USD","LU1066051498.USD","LU1066053197.SGD","SG9999015978.USD","BBH","TBXU","LU1778281490.HKD","LU1839511570.USD","GILD","BK4532","LU1674673428.USD","LU1430594728.SGD","LU1585245621.USD","SG9999015945.SGD","IBB","BK4568","IE00B19Z3B42.SGD","IE00B19Z3581.USD","LU1023059063.AUD","LU2468319806.SGD","IE00BKVL7J92.USD","BK4585","LU0114720955.EUR","LU0122379950.USD","TMED","LU0320765992.SGD","LU0965508806.USD","BK4578","LU0861579265.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664805360","title":"Eisai’s Lenvima Combo Trial in Liver Cancer Ends With Mixed but Market-Relevant Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2664805360","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664805360?lang=en_us&edition=fundamental","pubTime":"2026-09-04 00:30","pubTimestamp":1788453049,"startTime":"0","endTime":"0","summary":"Eisai Co ($ESALF) announced an update on their ongoing clinical study. The Phase 3 LEAP-012 study, run by Merck Sharp & Dohme with Eisai as partner...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eisais-lenvima-combo-trial-in-liver-cancer-ends-with-mixed-but-market-relevant-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eisais-lenvima-combo-trial-in-liver-cancer-ends-with-mixed-but-market-relevant-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IXJ","FTXH","GDOC","LU1974910355.USD","SG9999015358.SGD","LU2468319806.SGD","BK4588","LU2360032135.SGD","TRUH","HRTS","IE00BN8TJ469.HKD","LU0238689110.USD","LU1934455863.HKD","LU2361044865.SGD","BK4007","LU0320765489.SGD","PAWZ","LU2357627491.SGD","VHT","LU0477156953.USD","SG9999002224.SGD","LU1201861249.SGD","PPH","LU0859254822.USD","LU0211331839.USD","IE00B4R5TH58.HKD","RXL","SG9999001176.SGD","LU1037948897.HKD","BK4585","BMED","LU1585245621.USD","IYH","IE00BLSP4239.USD","BK4550","LU2125909247.SGD","IHE","LU0265550359.USD","JDOC","MRK","LU1057294990.SGD","IE0009355771.USD","LU0124676726.USD","LU0868494617.USD","LU1989771016.USD","LU2125154778.USD","XLV","LU1061106388.HKD","LU0208291251.USD","FHLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664805389","title":"Gilead’s Arcus-Backed Cancer Trial Reaches Completion, Setting Up a Key Immuno-Oncology Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2664805389","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664805389?lang=en_us&edition=fundamental","pubTime":"2026-09-04 00:30","pubTimestamp":1788453034,"startTime":"0","endTime":"0","summary":"Gilead Sciences ($GILD) announced an update on their ongoing clinical study. Gilead Partner Study Marks Milestone in First-Line Stomach Cancer Ther...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gileads-arcus-backed-cancer-trial-reaches-completion-setting-up-a-key-immuno-oncology-catalyst?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gileads-arcus-backed-cancer-trial-reaches-completion-setting-up-a-key-immuno-oncology-catalyst?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1023059063.AUD","LU1430594728.SGD","BK4532","LU1061106388.HKD","SG9999015945.SGD","LU1934455277.USD","IE00B19Z3B42.SGD","LU1066051498.USD","MEDI","LU0058720904.USD","LU0289739699.SGD","LU0965508806.USD","IE00BZ1G4Q59.USD","LU0965509101.SGD","LU1057294990.SGD","BIB","BBH","LU0122379950.USD","LU0882574055.USD","TBXU","LU1674673428.USD","LU0965509283.SGD","LU2089984988.USD","LU0861579265.USD","IE00B19Z3581.USD","LU1066053197.SGD","SG9999015952.SGD","TMED","LU1778281490.HKD","LU1585245621.USD","LU2112291526.USD","BK4588","BK4583","IBB","IE00B7SZLL34.SGD","IBBQ","IE00BKVL7J92.USD","BK4139","LU1037948541.HKD","GILD","BMED","IE00B3T34201.USD","LU2324357040.USD","LU2468319806.SGD","LU0823416689.USD","LU1571399168.USD","BK4566","LU1934455194.USD","SG9999015978.USD","LU1839511570.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664031788","title":"Summit Therapeutics Says it is Beating Merck with Its Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2664031788","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664031788?lang=en_us&edition=fundamental","pubTime":"2026-09-04 00:00","pubTimestamp":1788451200,"startTime":"0","endTime":"0","summary":"Shares of the drug developer Summit Therapeutics were up more than 12% Thursday morning on news that its drug is performing well in a Chinese lung cancer study.Summit stock jumped to $16.46 after the ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0868494617.USD","BK4550","BK4559","LU0266013472.USD","LU1585245621.USD","PAWZ","FHLC","SMMT","LU2461242641.AUD","LU1057294990.SGD","GDOC","LU1983299246.USD","LU1201861249.SGD","LU2023250504.SGD","SG9999002232.USD","LU2491050154.USD","LU0320765489.SGD","LU1037948897.HKD","FTXH","SG9999001176.SGD","SG9999001440.SGD","SGXZ57979304.SGD","LU2433249047.HKD","LU2089984988.USD","LU2125909247.SGD","TRUH","HRTS","LU0965509010.AUD","LU0965509283.SGD","LU0130517989.USD","LU0238689110.USD","LU1116320901.HKD","LU0477156953.USD","IE0002141913.USD","LU2357627491.SGD","LU1037948541.HKD","LU0208291251.USD","MRK","SG9999014559.SGD","LU0070302665.USD","LU1934455863.HKD","LU1032466523.USD","LU0689626769.HKD","SG9999014542.SGD","LU0942090050.USD","LU2125154935.USD","LU2125909593.SGD","LU0432979614.USD","VHT","LU1066051225.USD","LU1934455277.USD","IXJ","IE00BFTCPJ56.SGD","LU0265550359.USD","IHE","LU1974910355.USD","BK4585","LU0203347892.USD","LU1989772840.SGD","LU2125154778.USD","LU2106854487.HKD","LU1917777945.USD","JDOC","LU0098860793.USD","SG9999001176.USD","LU1066053197.SGD","LU1941712264.USD","IE0009355771.USD","BK4516","IE00BLSP4239.USD","SG9999013999.USD","LU2361044949.HKD","LU0965509101.SGD","LU0124676726.USD","LU0122379950.USD","LU0130102774.USD","BK4534","RXL","SG9999014567.USD","BK4533","IE00BBT3K403.USD","LU1093756325.SGD","LU2488822045.USD","LU2112291526.USD","LU1093756168.USD","LU1116320737.USD","LU2491050071.SGD","LU1923622614.USD","LU1929549753.HKD","LU0006306889.USD","LU1291159041.SGD","BK4007","LU1430594728.SGD","IE00B4R5TH58.HKD","LU0234572021.USD","LU2023250843.SGD","LU0965508806.USD","LU1035773651.USD","BK4139","LU1699723380.USD","IE00BSNM7G36.USD","LU1066051498.USD","LU0985320562.USD","SG9999014575.USD","IE00B1BXHZ80.USD","LU0859254822.USD","LU2360032135.SGD","BK4588","LU1066051811.HKD","LU0861579265.USD","LU0648001328.SGD","LU0211331839.USD","IE00BN8TJ469.HKD","LU1989772923.USD","LU2361045086.USD","IE00BJJMRZ35.SGD","LU1571399168.USD","BMED","LU2468319806.SGD","LU0265550946.USD","IE000M9KFDE8.USD","LU1023059063.AUD","SG9999015341.SGD","SG9999015358.SGD","LU1061106388.HKD","LU2324357040.USD","IYH","IE00BLSP4452.SGD","LU0289739699.SGD","LU1069347547.HKD","SG9999002224.SGD","IE00B2B36J28.USD","LU1941712348.USD","XLV","LU2491049909.HKD","LU0868494708.USD","LU0106261372.USD","IE00BJT1NW94.SGD","LU0823416689.USD","LU1162221912.USD","LU0058720904.USD","LU0320765646.SGD","LU0203345920.USD","LU2361044865.SGD","LU1934455194.USD","LU1989771016.USD","PPH","LU0980610538.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664487978","title":"Eikon Therapeutics Names Ching-Pin Chang as Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2664487978","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664487978?lang=en_us&edition=fundamental","pubTime":"2026-09-03 19:32","pubTimestamp":1788435147,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics names Ching-Pin Chang as chief scientific officerEikon Therapeutics named Ching-Pin “CP” Chang executive vice president, chief scientific officer.Chang joins from Bristol Myers Squi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL9l9Cns:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","BK4550","BMED","NDAQ","BBH","GILD","LU1093756168.USD","IBB","LU1236620834.HKD","LU2095319765.USD","LU2360032135.SGD","BK4585","LU1023059063.AUD","LU2242646821.SGD","LU2133065610.SGD","IHE","LU0109394709.USD","BIB","LU0306807586.USD","LU1585245621.USD","FTXH","LU0321505868.SGD","IBBQ","BMY","SG9999014021.USD","LU0114720955.EUR","LU1839511570.USD","IE00BKPKM429.USD","IE00BQXX3D17.EUR","TBXU","LU0267386448.USD","LU0965509010.AUD","LU1291159041.SGD","EIKN","MEDI","LU2087621335.USD","LU2089984988.USD","LU1934455194.USD","BCDF","IE00BN0W2V16.EUR","LU2242652126.USD","LU0859254822.USD","LU1057294990.SGD","LU1983299246.USD","LU1718418525.SGD","IE00B64PRP62.GBP","LU0122379950.USD","TMED","LU2125154778.USD","IE00BQXX3C00.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664875497","title":"Biogen, Eisai announce NMPA of China approves subcutaneous Leqembi","url":"https://stock-news.laohu8.com/highlight/detail?id=2664875497","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664875497?lang=en_us&edition=fundamental","pubTime":"2026-09-03 18:10","pubTimestamp":1788430218,"startTime":"0","endTime":"0","summary":"Eisai (ESAIY) and Biogen (BIIB) announced that the National Medical Products Administration of China has approved the subcutaneous formulation, the...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biogen-eisai-announce-nmpa-of-china-approves-subcutaneous-leqembi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biogen-eisai-announce-nmpa-of-china-approves-subcutaneous-leqembi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0234570918.USD","LU0109394709.USD","BK4533","BK4588","BK4532","BIIB","IE00B19Z9P08.USD","LU0320765992.SGD","ESAIY","IE00B19Z9Z06.USD","BMED","IE00B894F039.SGD","BK4007","LU0889565916.HKD","BK4139","BK4585","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664878960","title":"Nokia announces commercial agreement with BeeHealthy","url":"https://stock-news.laohu8.com/highlight/detail?id=2664878960","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664878960?lang=en_us&edition=fundamental","pubTime":"2026-09-03 17:05","pubTimestamp":1788426309,"startTime":"0","endTime":"0","summary":"Nokia (NOK) announced a commercial agreement with BeeHealthy, a digital healthcare platform, to integrate Nokia’s Network as Code technology into t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nokia-announces-commercial-agreement-with-beehealthy-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nokia-announces-commercial-agreement-with-beehealthy-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4020","BK4547","IE00BMPRXN33.USD","NOK","TCAF","BK4550","BMED","EKG","HEAL","DTEC","FDHT","MDTX","IE00BMPRXR70.SGD","ANEW","VHT","GDOC","LNOK","LU0006061336.USD","NOBL","IXJ","HTEC","CGCV","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108699787","title":"Gan&Lee Receives Clinical Trial Approval for GZC8072 Tablet in New Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=1108699787","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108699787?lang=en_us&edition=fundamental","pubTime":"2026-09-03 16:34","pubTimestamp":1788424482,"startTime":"0","endTime":"0","summary":"Gan&Lee Pharmaceuticals (SH: 603087) announced that its wholly-owned subsidiary, Gan&Lee Pharmaceuticals Shandong Co., Ltd., has received the \"Drug Clinical Trial Approval Notice\" from the National...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","MDTX","IBBJ","IBBQ","BMED","PSYK","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108389066","title":"ST Renfu Initiation of Phase II Clinical Study for Novel Postoperative Pain Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=1108389066","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108389066?lang=en_us&edition=fundamental","pubTime":"2026-09-03 16:16","pubTimestamp":1788423398,"startTime":"0","endTime":"0","summary":"ST Renfu (600079.SH) announced that its controlled subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (in which the company holds an 80% stake), has commenced a Phase II clinical trial for its...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","BK0012","BK0096","BK0028","IBBJ","BK0188","BK0185","BK0070","BK0239","MDTX","BMED","600079","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664821695","title":"EDX Medical ramps up cancer and pneumonia diagnostics as losses widen amid growth push","url":"https://stock-news.laohu8.com/highlight/detail?id=2664821695","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664821695?lang=en_us&edition=fundamental","pubTime":"2026-09-03 14:10","pubTimestamp":1788415817,"startTime":"0","endTime":"0","summary":"An update from TECC Capital Plc ( ($GB:EDX) ) is now available. EDX Medical Group has published its annual report for the year to 31 March 2026, hi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/edx-medical-ramps-up-cancer-and-pneumonia-diagnostics-as-losses-widen-amid-growth-push?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/edx-medical-ramps-up-cancer-and-pneumonia-diagnostics-as-losses-widen-amid-growth-push?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664219838","title":"EKF Diagnostics cancels 50,000 shares in latest buyback move","url":"https://stock-news.laohu8.com/highlight/detail?id=2664219838","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664219838?lang=en_us&edition=fundamental","pubTime":"2026-09-03 14:10","pubTimestamp":1788415804,"startTime":"0","endTime":"0","summary":"An update from EKF Diagnostics Holdings ( ($GB:EKF) ) is now available. EKF Diagnostics Holdings plc, an AIM-quoted global diagnostics group based ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ekf-diagnostics-cancels-50000-shares-in-latest-buyback-move?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ekf-diagnostics-cancels-50000-shares-in-latest-buyback-move?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664296258","title":"Jefferies Reaffirms Their Hold Rating on Merck KGaA (0O14)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664296258","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664296258?lang=en_us&edition=fundamental","pubTime":"2026-09-03 13:25","pubTimestamp":1788413115,"startTime":"0","endTime":"0","summary":"Jefferies analyst James Vane maintained a Hold rating on Merck KGaA today and set a price target of €144.00. According to TipRanks, Vane is an anal...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-reaffirms-their-hold-rating-on-merck-kgaa-0o14-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-reaffirms-their-hold-rating-on-merck-kgaa-0o14-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0070302665.USD","LU1934455863.HKD","LU1032466523.USD","LU0689626769.HKD","SG9999014542.SGD","LU0648001328.SGD","LU0942090050.USD","IE00BBT3K403.USD","LU2125154935.USD","LU0432979614.USD","VHT","PPH","PAWZ","IXJ","IE00BFTCPJ56.SGD","LU0265550359.USD","IE00BJJMRZ35.SGD","FHLC","IHE","LU1989772840.SGD","GDOC","BMED","LU2468319806.SGD","LU0265550946.USD","SG9999002232.USD","LU1430594728.SGD","FTXH","SG9999001176.SGD","IYH","LU1917777945.USD","JDOC","IE00B2B36J28.USD","LU1941712348.USD","LU1035773651.USD","SGXZ57979304.SGD","XLV","LU1941712264.USD","LU1162221912.USD","TRUH","HRTS","LU0058720904.USD","LU0320765646.SGD","LU0985320562.USD","RXL","LU2357627491.SGD","LU2360032135.SGD","LU1037948541.HKD","MRK","LU1066051811.HKD","LU0980610538.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664262218","title":"Nokia and BeeHealthy bring network-based verification to digital healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2664262218","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664262218?lang=en_us&edition=fundamental","pubTime":"2026-09-03 13:00","pubTimestamp":1788411600,"startTime":"0","endTime":"0","summary":"Press ReleaseNokia and BeeHealthy bring network-based verification to digital healthcare Nokia’s Network as Code platform replaces SMS one-time passcodes, provides seamless, secure access to BeeHealth","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/03/3355636/0/en/nokia-and-beehealthy-bring-network-based-verification-to-digital-healthcare.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FDHT","IE00BMPRXR70.SGD","BK4585","BK4588","LU0006061336.USD","LNOK","EKG","BMED","GDOC","BK4020","ANEW","IE00BMPRXN33.USD","DTEC","CGCV","HTEC","HEAL","NOK","IXJ","MDTX","NOBL","VHT","BK4547","TCAF","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664823499","title":"Biogen : Piper Sandler Raises Target Price to $245 from $225","url":"https://stock-news.laohu8.com/highlight/detail?id=2664823499","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664823499?lang=en_us&edition=fundamental","pubTime":"2026-09-03 11:00","pubTimestamp":1788404422,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nFWN44U0YT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B19Z9P08.USD","BK4139","BMED","LU0889565916.HKD","LU0320765992.SGD","LU0234570918.USD","BK4585","BIIB","LU0109394709.USD","PBE","BK4588","BK4533","IE00B894F039.SGD","IE00B19Z9Z06.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}